| Name | Title | Contact Details |
|---|---|---|
Stephen Motte |
Chief Financial Officer | Profile |
VNA is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedPro Services is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Ohio Bureau Of Workers' Compensation is a Independence, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since 1949, Gracepoint has cared for people like Rachel who needed a combination of intense therapies combined into her school day to thrive, graduate and find a job she loves. At Gracepoint, adults and children and their families have access to 26 board-certified psychiatrists, therapeutic specialists and 26 locations throughout Tampa Bay. Gracepoint`s mission is educating, advocating and giving hope to people touched by behavioral health and developmental challenges.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic